<DOC>
	<DOCNO>NCT01620554</DOCNO>
	<brief_summary>Prospective , multicenter , double-blind , phase II , randomize , dose-response study 5 parallel group ( dose-range ) .</brief_summary>
	<brief_title>Dose-range Finding Study BF2.649 Effect Patients With Obstructive Sleep Apnea ( OSA )</brief_title>
	<detailed_description>Obstructive sleep apnea ( OSA ) relatively common condition estimate affect 2 4 % middle-aged adult The study medication BF2.649 test novel , highly potent , selective , orally active inverse agonist histamine H3 receptor , therefore strengthen histaminergic transmission brain increase wakefulness EDS characterize daytime somnolence sudden sleep episode . This problem several consequence , e.g. , impairment quality life , interference activity daily live handicap management social family affair . The primary endpoint study measure change well-validated Epworth sleepiness scale ( ESS ) . The ESS simple self-administered 8-item questionnaire . The outcome get impression level daytime sleepiness several real-life situation . In study , patient treat 2 week , randomly assign one 5 arm ( BF2.649 one 4 possible dosage placebo ) . The patient attend end-of-treatment visit , order ass particularly ESS score .</detailed_description>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<criteria>Main inclusion Criteria : Patient OSA ( treat nCPAP ) still complain EDS Epworth Sleepiness Scale score &gt; = 11 Main exclusion Criteria : Patient suffer chronic severe insomnia accordance International Classification Sleep Disorders , without OSA</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Sleep disorder</keyword>
	<keyword>Obstructive Sleep Apnoea</keyword>
	<keyword>Excessive Daytime Sleepiness</keyword>
</DOC>